roneverson
Forum Replies Created
-
AuthorPosts
-
February 5, 2017 at 9:25 pm in reply to: New studies show a possible benefit of combining Gemcitabine, #93755roneversonSpectator
My wife’s biopsy was done was done through an ERCP. As I understand it, as they passed by the gall bladder & lymph nodes, they could see that they were affected & sampled through the internal endoscopy tube. Pretty amazing that they can install stents, take biopsies and perform radio frequency ablation all through the tube.
Ron Everson
roneversonSpectatorVictoria,
The biopsy had to be a needle biopsy, since it was done endoscopically. UCH does the testing in their own pathology lab.
Ron Everson
roneversonSpectatorA biopsy was performed during the initial endoscopy procedure. Molecular tests revealed no mutations, which seems to make it difficult to target.
We have been stymied by the recurring infections and wanted to get her stable so that we could begin chemo in order to get something started. We wanted to go directly to clinical trials, but most of those require that you have failed at the conventional chemo 1st. Our plan is still to go to a clinical trial, whether it be for a Ketruda-type drug, or T-cell therapy. MD Anderson confirmed that they only consider clinical trials for those that have failed at the conventional treatment, No sense wasting time waiting for a 2nd opinion that will tell us the same thing. Our 2nd opinion is alternative therapies.
When they replaced the right stent and drained out a bunch of yellow stuff, they considered putting in an external drain on the left side, since they weren’t able to get a stent in that side. The team decided against it when tests showed there was some drainage occurring on the left side, although not as much as they would like. I got the impression that our UCH team did not favor the external drains, perhaps because of the risk of infection.
Anyway, we are trying to get some chemo under out belt to knock it down a little. Hopefully it will affect the cancer in the lungs and lymph nodes as well. We plan to get into a clinical trial that utilizes immunotherapy or T-cell therapy early in 2017.
We’re also using a Rife machine, targeting the cancer with radio frequencies. Our particular model is the Perl M+ with 2 of the Progen II frequency generators.
Hopefully something will work.
Ron Everson
Cortez, Colorado -
AuthorPosts